Leerink Partners Reaffirms Buy Rating on Rapport Therapeutics
Leerink Partners maintains a buy rating on Rapport Therapeutics with a $52 price target, a 29.81% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on Rapport Therapeutics, setting a $52 price target on June 24, 2026.
- Leerink Partners's $52 price target implies 29.81% upside from Rapport Therapeutics, Inc.'s ($RAPP) current $40.06 share price.
- Shares of NasdaqGM:RAPP traded near $40 on Friday, with a market cap of $1.86 billion and a 52-week high of $42.27.
- Rapport Therapeutics saw insider buying from multiple executives on June 10, 2026, with each purchasing 15,200 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Leerink Partners reiterated its buy rating on Rapport Therapeutics, Inc. (NasdaqGM:RAPP), setting a price target of $52. Analyst Marc Goodman reaffirmed his positive outlook on the stock, which is trading around $40.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Rapport Therapeutics, Inc. Stock Down 17.9%
Shares of NasdaqGM:RAPP traded near $40 on Friday. Rapport Therapeutics has a market cap of approximately $1.86 billion. Despite not being currently profitable, the forward P/E ratio is not meaningful. The stock has a 52-week low of $11.05 and a high of $42.27. It has a 50-day moving average of $37.05 and a 200-day moving average of $30.30. The company maintains a strong financial position with a current ratio of 27.08 and a quick ratio of 26.64, and a debt-to-equity ratio of 2.29.
$RAPP price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in Rapport Therapeutics
Several institutional investors have adjusted their positions in Rapport Therapeutics. FMR LLC increased its holdings by 57,074 shares, ending with 7,168,939 shares valued at about $224.3 million, a 0.8% increase. TRV GP V, LLC held steady at 7,135,233 shares worth $223.3 million. ARCH VENTURE MANAGEMENT, LLC also maintained its position with 3,728,738 shares valued at $116.7 million. Meanwhile, Capital International Investors reduced its stake by 304,556 shares to 3,097,973 shares, valued at $96.9 million, a 9.0% decrease. Cormorant Asset Management, LP cut its holdings by 70,000 shares to 2,957,521 shares, valued at $92.5 million, a 2.3% decrease.
Insider Buying and Selling at Rapport Therapeutics, Inc.
On June 10, 2026, several insiders at Rapport Therapeutics purchased shares. John Maraganore, Paul Silva, Wendy Young, Ramiro Sanchez, James Healy, and Reid Huber each bought 15,200 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, Leerink Partners initiated coverage with a buy rating and a $52 price target. BTIG, on May 21, 2026, maintained its buy rating with a $65 target. Truist Securities assumed coverage with a buy rating and a $56 target on May 19, 2026. The consensus among analysts is a strong buy, with a target mean price of approximately $56.64 based on 11 analyst opinions.
About Rapport Therapeutics
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. Led by CEO Abraham N. Ceesay, the company focuses on developing small molecule medicines for central nervous system disorders. Its lead product candidate, RAP-219, targets focal epilepsy and other CNS disorders. The firm also works on treatments for chronic pain and hearing disorders. Founded in 2022, Rapport has 84 employees dedicated to advancing its innovative therapies.
Bottom Line
Rapport Therapeutics continues to attract attention with its promising pipeline and recent analyst endorsements. The reiterated buy rating from Leerink Partners underscores confidence in the company's growth prospects. Investors will be watching closely as the company progresses with its clinical developments.
Get Rapport Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RAPP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.